De novo acute myeloid leukemia in adults: Suppression of MicroRNA-223 is independent of LMO2 protein expression but associate with adverse cytogenetic profile and undifferentiated blast morphology

Applied Immunohistochemistry and Molecular Morphology

Volumn 23, Issue 10, 2015, Pages 733-739

  Akhter, Ariz ^a   Patel, Jay L ^a   Farooq, Fahad ^a   Qureshi, Abid ^a   Taher Rad, Meer Shahbani ^a   Elyamany, Ghaleb ^b   Al Zahrani, Ali M ^b   Rashid Kolvear, Fariborz ^c   Mansoor, Adnan ^a  

^a FOOTHILLS HOSPITAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Prince Sultan Military Medical City   (Saudi Arabia)

Author keywords

Acute myeloid leukemia; AML NOS with differentiation; Cytogenetic risk groups; FAB classification; LMO2 protein; microRNA; MIR223; WHO classification

Indexed keywords

LIM HOMEODOMAIN PROTEIN; LMO2 PROTEIN; MICRORNA 223; UNCLASSIFIED DRUG; LIM PROTEIN; LMO2 PROTEIN, HUMAN; MICRORNA; MIRN223 MICRORNA, HUMAN; ONCOPROTEIN; RNA; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANEUPLOIDY; ARTICLE; BONE MARROW BIOPSY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMEDIATE RISK POPULATION; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; ADOLESCENT; BIOSYNTHESIS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIM DOMAIN PROTEINS; MALE; MICRORNAS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RETROSPECTIVE STUDIES; RNA, NEOPLASM; SURVIVAL RATE;

EID: 84947227056     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000145     Document Type: Article

References (43)

1. Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer. 2003;3:89-101.
2. Frohling S, Scholl C, Gilliland GL, et al. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol. 2005;23:6285-6295.
3. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107:2099-2107.
4. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene and microRNA expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28:598-604.
5. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European Leukemia Net study. J Clin Oncol. 2009;27:5195-5201.
6. Foran J. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematol Am Soc Hematol Educ Prog. 2010;2010:47-55.
7. Jiang A, Jiang H, Brandwein J, et al. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. Leuk Res. 2011;35:492-498.
8. Sanders M, Valk P. The evolving molecular genetic landscape in acute myeloid leukaemia. Curr Opin Hematol. 2013;20:79-85.
9. Wang Q, Stacy T, Binder M, et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA. 1996;93: 3444-3449.
10. Izraeli S. Leukaemia - a developmental perspective. Br J Haematol. 2004;126:3-10.
11. Borregaard N, Theilgaard-Monch K, Sorensen OE, et al. Regulation of human neutrophil granule protein expression. Curr Opin Hematol. 2001;8:23-27.
12. Cheng T, Shen H, Giokas D, et al. Temporal mapping of gene expression levels during the differentiation of individual primary hematopoietic cells. Proc Natl Acad Sci USA. 1996;93: 13158-13163.
13. Dahl R, Walsh JC, Lancki D, et al. Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating factor. Nat Immunol. 2003;4:1029-1036.
14. Theilgaard-Monch K, Jacobsen LC, Borup R, et al. The transcrip-tional program of terminal granulocytic differentiation. Blood. 2005;105:1785-1796.
15. Pulikkan JA, Dengler V, Peramangalam PS, et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood. 2010;115: 1768-1778.
16. Fazi F, Rosa A, Fatica A, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell. 2005;123:819-831.
17. Fatica A, Fazi F. MicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tune. Int J Mol Sci. 2013;14:20930-20953.
18. Schuler A, Schwieger M, Engelmann A, et al. The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. Blood. 2008;111:4532-4541.
19. + myeloid-derived suppressor cells from bone marrow cells. Int J Cancer. 2011;129: 2662-2673.
20. Felli N, Pedini F, Romania P, et al. MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis. Haematolo-gica. 2009;94:479-486.
21. Warren AJ, Colledge WH, Carlton MB, et al. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell. 1994;78:45-57.
22. Jin-Yun Y, Fang W, Jia Y, et al. MicroRNA-223 reversibly regulates erythroid and megakaryocytic differentiation of K562 cells. J Cell Mol Med. 2009;13:4551-4559.
23. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood. 2009;113:3754-3764.
24. Patel JL, Pournazari P, Haggstrom SJ, et al. LMO2 (LIM Domain Only 2, Rhombotin-Like 1) is expressed in a subset of acute myeloid leukemia and correlates with normal cytogenetics. Histopathology. 2014;64:226-233.
25. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;14:937-951.
26. Arber D, Brunning R, Orazi A, et al. Acute Myeloid Leukemia, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008.
27. Arber D, Brunning R, Beau ML, et al. Acute Myeloid Leukemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 4 ed. Lyon: IARC Press; 2008.
28. Fazi F, Racanicchi S, Zardo G, et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO onco-protein. Cancer Cell. 2007;12:457-466.
29. Jongen-Lavrencic M, Sun SM, Dijkstra MK, et al. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008;111:5078-5085.
30. Cammarata G, Augugliaro L, Salemi D, et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol. 2010;85:331-339.
31. Jian P, Li ZW, Fang TY, et al. Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663. J Hematol Oncol. 2011;4:20.
32. Garzon R, Pichiorri F, Palumbo T, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene. 2007;26:4148-4157.
33. Nervi C, Fazi F, Rosa A, et al. Emerging role for microRNAs in acute promyelocytic leukemia. Curr Top Microbiol Immunol. 2007;313:73-84.
34. Agatheeswaran S, Singh S, Biswas S, et al. BCR-ABL mediated repression of miR-223 results in the activation of MEF2C and PTBP2 in chronic myeloid leukemia. Leukemia. 2013;27:1578-1580.
35. Guido M, Krzysztof M, Michael DR, et al. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2011;117:1121-1129.
36. Basile S, Nathalie M, Benjamin HK, et al. microRNA-29c and microRNA-223 down-regulation has in-vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 2009;113:5237-5245.
37. Zardo G, Ciolfi A, Vian L, et al. Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. Blood. 2012;119:4034-4046.
38. Johnnidis JB, Harris MH, Wheeler RT, et al. Regulation of progenitor cell proliferation and granulocyte function by micro-RNA-223. Nature. 2008;451:1125-1129.
39. Krivtsov AV, Twomey D, Feng Z, et al. Transformationfrom committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;441:818-822.
40. Cante-Barrett K, Pieters R, Meijerink JP. Myocyte enhancer factor 2C in hematopoiesis and leukemia. Oncogene. 2014;33:403-410.
41. Nian W, Ao X, Wu Y, et al. miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulinlike growth factor-1 receptor and cyclin-dependent kinase 2. Oncol Lett. 2013;6:359-366.
42. Diffner E, Beck D, Gudgin E, et al. Activity of a heptad of transcription factors is associated with stem cells program and clinical outcome in acute myeloid leukemia. Blood. 2013;121:2289-2300.
43. Martens JH, Mandoli A, Simmer F, et al. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood. 2012;120: 4038-4048.